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Recent studies have highlighted the deleterious role of cardiovascular risk factors, including hypertension, on the incidence of
dementia. Although midlife hypertension is associated with later development of dementia, the role of late-life hypertension
remains unclear. We explored the association of hypertension and its treatment with incident dementia in 13978 older
(median = 74 years) adults followed from 1981 to 2010 (median = 13 years) and calculated risk estimates using Cox regression
analysis in two age groups (<75 and 75+ years) in men and women separately. Dementia status was determined from in-
person evaluations, followup questionnaires, hospital data, and death certiﬁcates. In the older women, current users of blood
pressure medication at baseline had a 26% increased risk of dementia (95% CI 1.06–1.51). In the younger men, those with
untreated hypertension and those with past use of blood pressure medication use had about a 30% nonsigniﬁcant increased
risk of dementia. High blood pressure and its treatment appear to have diﬀerent eﬀects in men and women and in the old and
older.
1.Introduction
As a result of an aging population, the prevalence of demen-
tia, which in 2005 aﬀected 24.3 million people worldwide,
is expected to aﬄict more than 81 million by 2040 [1].
Recent studies have highlighted the deleterious role of
cardiovascular risk factors, including hypertension, on the
incidence of dementia and suggested that their therapeutic
control may reduce risk of development of dementia in later
life [2, 3]. Several longitudinal studies have found midlife
hypertension to be related to dementia (reviewed in [3, 4]),
but the role of late-life hypertension remains unclear.
The focus of the present study was to examine the
possible role of hypertension and its treatment as predictors
of dementia in elderly men and women. We report here the
results in a large cohort (nearly 14000) of elderly (median
a g e7 4y e a r s )m e na n dw o m e nf o l l o w e df o ru pt o2 9y e a r s
(median 13 years).
2. Methods
The Leisure World Cohort Study was established in the
early 1980s when 13978 residents of a California retirement
community (Leisure World Laguna Hills) completed a postal
health survey. Residents were recruited in four waves: those
who owned homes in Leisure World on June 1, 1981;
new residents who had moved into the community and
were living there on June 1, 1982; on June 1, 1983; on
October 1, 1985. The baseline survey asked demographic
information, brief medical history, medication use, and
personalhabitsincludingcigarettesmoking,exercise,alcohol
consumption, and beverage intake. The subjects were asked
if a doctor ever told them they had high blood pressure
and if they had ever taken or were currently taking speciﬁc
medications including “Reserpine (please include Raudixin,
Ser-Ap-Es, Hydropres, Rauwolﬁas, Metatensin)” and “other
blood pressure medication, water pills.” The population and2 International Journal of Hypertension
the cohort are mostly Caucasian, well educated, upper-
middle class, and elderly.
Followup of the cohort is maintained by periodic
resurvey (1983, 1985, 1992, 1998), review of local hospital
discharge data (1981–2001), and determination of vital
status by search of governmental and commercial death
indexes and ascertainment of death certiﬁcates. The 1983
followup questionnaire asked new diagnoses of high blood
pressure since the baseline survey. The 1998 questionnaire
again asked if the subject had ever been told by a doctor that
they had high blood pressure and the frequency of use of
high blood pressure medication.
Dementia cases were identiﬁed from in-person evalua-
t i o n sa sp a r to fad e m e n t i as t u d y[ 5], hospital records, death
certiﬁcates, and/or followup questionnaires with the date of
diagnosis being the date at which dementia was ﬁrst men-
tioned. Participants were followed to dementia diagnosis,
deathorDecember31,2010,whichevercameﬁrst.Todate37
cohort members have been lost to followup; search of death
indices did not reveal that these individuals were deceased.
Chi-square tests were used for comparison of categorical
variables and t-tests for testing diﬀerences in means of
continuous variables. Age-adjusted hazard ratios (HRs) of
dementia associated with hypertension were estimated using
Coxproportionalhazardregressionanalysiswithageatstudy
entry being the age when the baseline survey was completed
and the event of interest being age at dementia. Separate
analyses were done for two age groups: <75 years and 75+
years of age at baseline, with additional adjustment for age
(continuous). Because women diﬀe rf r o mm e no nm a n y
variables, women live longer on average than men, and
for comparison with other studies limited to one sex, we
performed separate analyses for men and women. Statistical
analyseswereperformedusingSASversion9.2(SASInstitute
Inc., Cary, NC). No adjustment in the P values was made for
multiple comparisons.
Previous reports present details of the methods and
the reliability of recall of the self-reported information [6–
9]. The Institutional Review Boards of the University of
Southern California and the University of California, Irvine
approved the study.
3. Results
At study entry, the participants’ mean and median age was
74 years (standard deviation = 7). By December 31, 2010,
2429 participants had been diagnosed with dementia and
13134 had died. Age at dementia ranged from 66 to 106 years
(median, 90 years). Dementia cases were identiﬁed by The
90+ Study (n = 690), hospitalization record (n = 199),
followup questionnaire (n = 264), and death certiﬁcation
(n = 1768); these categories are not mutually exclusive.
Characteristics of the study participants are shown in
Table 1.W o m e nd i ﬀered signiﬁcantly from men on all these
variables (P<0.001 for all variables except cancer where
P<0.02).
Tables 2 and 3 show the age-adjusted HRs of incident
dementia for hypertension and its treatment for women and
Table 1: Characteristics of participants by sex, The Leisure World
Cohort.
Number
Men Women
5101 8877
Mean SD Mean SD
Age at baseline (years) 74 7.2 73 7.4
Age at last followup (years) 86 7.0 88 7.0
Followup years 11 7.3 15 7.7
Active activities (hrs/day) 1.1 1.3 0.9 1.1
Other less strenuous activities (hrs/day) 3.6 2.7 4.4 2.6
Alcohol (drinks/day) 1.6 1.5 1.2 1.2
Caﬀeine (mg/day) 176 172 168 166
Body mass index (kg/m2) 24 2.9 23 3.5
No. % No. %
Medical history
High blood pressure 1843 36 3620 41
Angina 738 14 839 9
Heart attack 847 17 588 7
Stroke 370 7 333 4
Cancer 826 16 1574 18
Diabetes 425 8 442 5
Rheumatoid arthritis 226 4 608 7
Smoke
Never 1708 33 4883 55
Past 2953 58 2880 32
Current 437 9 1106 12
Deceased by December 31, 2010 4930 97 8204 92
men, respectively. Forty-three percent of subjects reported
not having high blood pressure and not taking hypertensive
medication. Of the remaining with high blood pressure,
about 21% took no medication, 18% took medication in
the past but not currently, and 18% were currently taking
blood pressure medication. The only signiﬁcant risk factor
for dementia was current blood pressure medication (HR =
1.26, 95% CI 1.06–1.51) in women aged 75+ years. No eﬀect
of current treatment was seen in men. The greatest (though
nonsigniﬁcant) risks in men were found among men less
than 75 years old with untreated hypertension (HR = 1.27,
95% CI 0.95–1.70) and with past use of blood pressure
medication (HR = 1.33, 95% CI 1.00–1.79).
Followup questionnaires identiﬁed few additional indi-
viduals with hypertension. Of the 9731 who returned the
1983 followup survey, 188 (2%) reported a new diagnosis
of high blood pressure. In 1998, 219 (11%) of 1963 who
returned the questionnaire reported having high blood
pressure in 1998 but not at baseline.
4. Discussion
InrecentyearsthestrictdivisionbetweenAlzheimer’sdisease
and vascular dementia has faded with advancing research
in neuropathology, neuroradiology, and epidemiology. Most
dementia patients, irrespective of their clinical diagnosis,International Journal of Hypertension 3
Table 2: Hazard ratios for dementia by hypertension and its treatment in men, Leisure World Cohort Study, 1981–2010.
Aged <75 years 75+ years
No. No. with dementia HR 95% CI No. No. with dementia HR 95% CI
Hypertension and treatment
No hypertension and no treatment 1160 153 1.00 1171 163 1.00
Hypertension but no treatment 495 66 1.27 0.95–1.70 480 51 1.02 0.75–1.41
Past treatment 449 64 1.33 1.00–1.79 384 42 0.92 0.66–1.30
Current treatment 430 42 1.00 0.71–1.41 532 56 1.01 0.74–1.37
Current hypertensive medication
No 2104 283 1.00 2035 256 1.00
Yes 430 42 0.89 0.64–1.24 532 56 1.02 0.76–1.36
Table 3: Hazard ratios for dementia by hypertension and its treatment in women, Leisure World Cohort Study, 1981–2010.
Aged <75 years 75+ years
No. No. with dementia HR 95% CI No. No. with dementia HR 95% CI
Hypertension and treatment
No hypertension and no treatment 2131 479 1.00 1522 345 1.00
Hypertension but no treatment 1054 177 0.88 0.74–1.05 937 155 0.91 0.76–1.11
Past treatment 1011 202 0.90 0.77–1.06 685 137 0.92 0.75–1.12
Current treatment 750 148 0.99 0.82–1.19 787 149 1.21 1.00–1.47
Current hypertensive medication
No 4196 858 1.00 3144 637 1.00
Yes 750 148 1.04 0.87–1.24 787 149 1.26 1.06–1.51
have mixed pathology (Alzheimer’s changes and cerebrovas-
cular lesions) at autopsy [10, 11]. High blood pressure has
long been understood to cause stroke, a risk factor for
vascular dementia. However, the association between blood
pressure and dementia is complex. Midlife hypertension
increases risk of cognitive impairment, Alzheimer’s disease,
and dementia (reviewed in [3, 4]).
Associations in longitudinal studies of late-life hyperten-
sion and dementia have been less consistent. Some found
blood pressure levels were higher in individuals who devel-
oped dementia [12], Alzheimer’s disease [13], or vascular
dementia [14] than in those who did not. In the Swedish
Longitudinal Population Study of 382 participants (aged 70
years) subjects who developed dementia had signiﬁcantly
higher systolic and diastolic blood pressures about 10 to
15 years before cognitive assessment than subjects without
dementia [12]. In the Kungsholmen Project, a community-
based cohort of 1270 participants (aged ≥75 years) in
Sweden followed for 6 years, 339 subjects were diagnosed
with dementia [13]. Subjects with high SBP (>180mmHg)
had a risk of 1.6 (95% CI 1.1–2.2) for dementia. High
DBP (>90mmHg) was not associated with increased risk.
In Hisayama Study, Japan, in which 828 people (aged 65–
98 years) were followed for 7 years, blood pressure was
not related to AD but 1 standard deviation increase in
SBP increased risk of vascular dementia 60% (95% CI 1.2–
2.2) [14]. The Adult Changes in Thought Study included
2356 participants aged ≥65 years followed for 8 years
during which time 380 developed dementia [15]. Only in
the youngest age group (65–74 years) did those with high
SBP (≥160mmHg) have a signiﬁcantly increased risk of
dementia (HR 1.6, 95% CI 1.01–2.55) and the risk declined
with advancing age to 0.64 (95% CI 0.32–1.30) in the
oldest age group (>85 years). In the Women’s Memory
Study blood pressure levels measured 5 and 9 years before
dementia assessment did not diﬀer signiﬁcantly between
dementedandnondemented[16].Othershaveobservedthat
history of hypertension was not related to dementia [17,
18], Alzheimer’s disease [19–22] but was related to vascular
dementia[22].Interestingly,intheCanadianStudyofHealth
and Aging, the presence of hypertension did not result in
cognitive deterioration across the cohort of subjects (mean
age 83 years) [23]. However, subjects with hypertension and
cognitive executive dysfunction increasingly progressed to
dementia (58% in ﬁve years) compared with normotensives
(28%) but not in those with hypertension and memory
dysfunction (74% versus 67%).
Our study extends the available literature on the role
of hypertension and dementia in the very elderly but has
several limitations. Information on hypertension and blood
pressure medication was self-reported; we performed no
blood pressure determinations. However, previous studies
in our population and others support the reliability of self-
reported health practices, drug usage, and medical history
of major chronic disease [8, 9]. Although changes over time
in all potential risk factors may aﬀect outcome, new cases of
hypertension were reported in only a small minority of sub-
jects. Additionally, the proportion of demented individuals4 International Journal of Hypertension
is undoubtedly an underestimate of the true incidence, and
we lacked clinical diagnoses of dementia based on standard
criteria for many subjects. Subjects with dementia who
had not been seen in person or hospitalized and were not
reported as having dementia at the time of the followup sur-
veys or on their death certiﬁcates were actually misclassiﬁed
into the nondemented group. This has, with all likelihood,
weakened the associations seen here. For these reasons our
results are preliminary and incomplete. Furthermore, our
subjects are from a select population—moderately aﬄuent,
highly educated, health conscious, and primarily Caucasian.
Although this may limit the generalizability of our results, it
reduces potential confounding by race, education, SES, and
presumed access to health care. Nonetheless, unrecognized
and uncontrolled confounders cannot be ruled out in this
study or any observational study.
Clinical trials of antihypertensive medication in older
subjects have also yielded inconsistent results (reviewed by
[2–4]).Randomizedcontrolledtrialshavedemonstratedthat
blood pressure-reducing agents decrease the incidence of
dementia in stroke patients (PROGRESS [24], HOPE [25])
and in older (≥60 years) patients with isolated systolic
hypertension (SYST-EUR) [26, 27], but this was not found
in SHEP [28], SCOPE [29], and HYVET-COG [30]. These
latter three included more elderly patients. The SHEP
(Systolic Hypertension in the Elderly Programme) trial of
4736 patients (mean age 72 years) found a nonsigniﬁcant
16%reductionindementiaintreatmentgroups.TheSCOPE
(Study on Cognition and Prognosis in the Elderly) study
of 4964 elderly (mean age 76 years) and HYVET-COG
(Hypertension in the Very Elderly Trial-cognitive function
assessment) of 3336 patients aged ≥80 years found no
eﬀect on cognitive decline, Alzheimer’s disease, or vascular
dementia. Since diﬀerent antihypertensive medications were
used by our study subjects as well as in the clinical trials
which looked for an eﬀect of medication on dementia
development, a speciﬁc class eﬀect cannot be ruled out.
Others have detailed the possible mechanisms by which
hypertension may increase risk of dementia (reviewed in [3,
4]). Hypertension may promote blood vessel wall thickening
leading to arteriosclerosis and lipohyalinosis; cause stroke,
focal ischemia, chronic hypoperfusion of the white matter,
and white matter lesions; cause microcirculation disorders
and endothelial dysfunction which may compromise the
function of the blood brain barrier leading to increased
vascular permeability and extravasation of protein into the
cerebral parenchyma.
Although not establishing a cause and eﬀect relationship
between incident dementia and high blood pressure and its
treatment, this large elderly cohort suggests an increased
risk of dementia in the younger (<75 years) men with
untreated hypertension and with past use of hypertensive
medication. This agrees with the ﬁndings of earlier studies
showing an increased risk of dementia with higher measured
blood pressure levels. In women the risk among current (at
baseline) users of blood pressure medication, which was the
strongest in the older age group (75+ years), highlights the
need for careful monitoring of blood pressure in the elderly.
Decline in blood pressure is common at ages above 75 years,
and the Kungsholmen Project found low blood pressure to
be associated with dementia risk (HR = 1.5, 95% CI 1.0–2.1)
[13]. Periods of hypotension, hypoperfusion and hypoxia
observed in subjects on antihypertensives might contribute
to cognitive decline via reduced cerebral blood ﬂow, causing
ischemic lesions in the brain.
5. Conclusion
Although treating hypertension has a clear eﬀect on stroke,
cardiovascular disease, and mortality, the eﬀect of hyper-
tension and its treatment on dementia is more complex.
While previous studies have found midlife hypertension to
be related to dementia, results for late-life hypertension and
its treatment are inconsistent. Our study in older adults
suggests that the eﬀect varies not only with age (with a
diﬀerence between those less than 75 years old and those 75+
yearsold)butalsowithsex.Futurestudiesexaminingtherole
of hypertension in older adults should perform sex-speciﬁc
analyses.
Acknowledgments
This research was funded by Grants from the National
Institutes of Health (R01CA32197 and R01AG21055), the
Errol Carroll Trust Fund, Wyeth-Ayerst Laboratories.
References
[1] C. P. Ferri, M. Prince, C. Brayne et al., “Global prevalence of
dementia: a Delphi consensus study,” The Lancet, vol. 366, no.
9503, pp. 2112–2117, 2005.
[2] S. A. Ligthart, E. P. M. van Charante, W. A. van Gool, and E.
Richard, “Treatment of cardiovascular risk factors to prevent
cognitive decline and dementia: a systematic review,” Vascular
Health and Risk Management, vol. 6, no. 1, pp. 775–785, 2010.
[3] E. Duron and O. Hanon, “Vascular risk factors, cognitve
decline,anddementia,”VascularHealthandRiskManagement,
vol. 4, no. 2, pp. 363–381, 2008.
[4] S. P. Kennelly, B. A. Lawlor, and R. A. Kenny, “Blood pres-
sure and dementia—a comprehensive review,” Therapeutic
Advances in Neurological Disorders, vol. 2, no. 4, pp. 241–260,
2009.
[5] M. M. Corrada, R. Brookmeyer, D. Berlau, A. Paganini-Hill,
and C. H. Kawas, “Prevalence of dementia after age 90: results
from The 90+ Study,” Neurology, vol. 71, no. 5, pp. 337–343,
2008.
[6] A. Paganini-Hill, R. K. Ross, and B. E. Henderson, “Prevalence
of chronic disease and health practices in a retirement
community,” Journal of Chronic Diseases,v o l .3 9 ,n o .9 ,p p .
699–707, 1986.
[7] A. Paganini-Hill, A. Chao, R. K. Ross, and B. E. Henderson,
“Exercise and other factors in the prevention of hip fracture:
the Leisure World Study,” Epidemiology, vol. 2, no. 1, pp. 16–
25, 1991.
[8] A. Paganini-Hill and A. Chao, “Accuracy of recall of hip frac-
ture, heart attack, and cancer: a comparison of postal survey
data and medical records,” American Journal of Epidemiology,
vol. 138, no. 2, pp. 101–106, 1993.International Journal of Hypertension 5
[9] A. Paganini-Hill and R. K. Ross, “Reliability of recall of drug
usageandotherhealth-relatedinformation,”AmericanJournal
of Epidemiology, vol. 116, no. 1, pp. 114–122, 1982.
[10] G. M. Savva, S. B. Wharton, P. G. Ince, G. Forster, F. E.
Matthews, and C. Brayne, “Age, neuropathology, and demen-
tia,” New England Journal of Medicine, vol. 360, no. 22, pp.
2302–2309, 2009.
[11] J. A. Schneider, Z. Arvanitakis, W. Bang, and D. A. Bennett,
“Mixed brain pathologies account for most dementia cases in
community-dwelling older persons,” Neurology, vol. 69, no.
24, pp. 2197–2204, 2007.
[12] I. Skoog, B. Lernfelt, S. Landahl et al., “15-year longitudinal
study of blood pressure and dementia,” The Lancet, vol. 347,
no. 9009, pp. 1141–1145, 1996.
[13] C. Qiu, E. von Strauss, J. Fastbom, B. Winblad, and L.
Fratiglioni, “Low blood pressure and risk of dementia in the
Kungsholmen Project: a 6-year follow-up study,” Archives of
Neurology, vol. 60, no. 2, pp. 223–228, 2003.
[14] T. Yoshitake, Y. Kiyohara, I. Kato et al., “Incidence and risk
factors of vascular dementia and Alzheimer’s disease in a
deﬁned elderly Japanese population: the Hisayama study,”
Neurology, vol. 45, no. 6, pp. 1161–1168, 1995.
[15] G. Li, I. C. Rhew, J. B. Shofer et al., “Age-varying association
between blood pressure and risk of dementia in those aged
65 and older: a community-based prospective cohort study,”
Journal of the American Geriatrics Society,v o l .5 5 ,n o .8 ,p p .
1161–1167, 2007.
[16] D. B. Petitti, V. C. Crooks, J. G. Buckwalter, and V. Chiu,
“Bloodpressurelevelsbeforedementia,”ArchivesofNeurology,
vol. 62, no. 1, pp. 112–116, 2005.
[17] C. Brayne, C. Gill, F. A. Huppert et al., “Vascular risks and
incidentdementia:resultsfromacohortstudyoftheveryold,”
Dementia and Geriatric Cognitive Disorders,v o l .9 ,n o .3 ,p p .
175–180, 1998.
[18] L. H. Kuller, O. L. Lopez, A. Newman et al., “Risk factors
for dementia in the Cardiovascular Health Cognition Study,”
Neuroepidemiology, vol. 22, no. 1, pp. 13–22, 2003.
[19] S. L. Tyas, J. Manfreda, L. A. Strain, and P. R. Montgomery,
“Risk factors for Alzheimer’s disease: a population-based, lon-
gitudinal study in Manitoda, Canada,” International Journal of
Epidemiology, vol. 30, no. 3, pp. 590–597, 2001.
[20] J. Lindsay, D. Laurin, R. Verreault et al., “Risk factors for
Alzheimer’s disease: a prospective analysis from the Canadian
StudyofHealthandAging,”AmericanJournalofEpidemiology,
vol. 156, no. 5, pp. 445–453, 2002.
[21] A. R. Borenstein, Y. Wu, J. A. Mortimer et al., “Developmental
andvascularriskfactorsforAlzheimer’sdisease,”Neurobiology
of Aging, vol. 26, no. 3, pp. 325–334, 2005.
[22] H. B. Posner, M.-X. Tang, J. Luchsinger, R. Lantigua, Y. Stern,
and R. Mayeux, “The relationship of hypertension in the
elderly to AD, vascular dementia, and cognitive function,”
Neurology, vol. 58, no. 8, pp. 1175–1181, 2002.
[23] S. Oveisgharan and V. Hachinski, “Hypertension, executive
dysfunction,andprogressiontodementia:theCanadianStudy
of Health and Aging,” Archives of Neurology, vol. 67, no. 2, pp.
187–192, 2010.
[24] C. Tzourio, C. Anderson, N. Chapman et al., “Eﬀects of blood
pressure lowering with perindopril and indapamide therapy
ondementiaandcognitivedeclineinpatientswithcerebrovas-
cular disease,” Archives of Internal Medicine, vol. 163, no. 9, pp.
1069–1075, 2003.
[25] J.Bosch,S.Yusuf,J.Pogueetal.,“Useoframiprilinpreventing
stroke:doubleblindrandomisedtrial,”BritishMedicalJournal,
vol. 324, no. 7339, pp. 699–702, 2002.
[26] F. Forette, M. L. Seux, J. A. Staessen et al., “Prevention
of dementia in randomised double-blind placebo-controlled
Systolic Hypertension in Europe (Syst-Eur) trial,” The Lancet,
vol. 352, no. 9137, pp. 1347–1351, 1998.
[27] F. Forette, M. L. Seux, J. A. Staessen et al., “The prevention
of dementia with antihypertensive treatment: new evidence
from the Systolic Hypertension in Europe (Syst-Eur) study,”
Archives of Internal Medicine, vol. 162, no. 18, pp. 2046–2052,
2002.
[28] SHEP Cooperative Research Group, “Prevention of stroke by
antihypertensivedrugtreatmentinolderpersonswithisolated
systolichypertension:ﬁnalresultsoftheSystolicHypertension
in the Elderly Program (SHEP),” Journal of the American
Medical Association, vol. 265, no. 24, pp. 3255–3264, 1991.
[29] H.Lithell,L.Hansson,I.Skoogetal.,“TheStudyonCognition
and Prognosis in the Elderly (SCOPE): principal results of a
randomizeddouble-blindinterventiontrial,”JournalofHyper-
tension, vol. 21, no. 5, pp. 875–886, 2003.
[30] R. Peters, N. Beckett, F. Forette et al., “Incident dementia
and blood pressure lowering in the Hypertension in the
Very Elderly Trial Cognitive Function Assessment (HYVET-
COG): a double-blind, placebo controlled trial,” The Lancet
Neurology, vol. 7, no. 8, pp. 683–689, 2008.